PlainPatent
USPTO 2015–2025 USPTO PatentsView Foreign Corporation

Wuhan YZY Biopharma Co., Ltd.

USPTO PatentsView assignee record - 9 granted patents across 4 technology areas, recorded in grant years 2015–2025. Grant-trend analysis is cross-referenced to USPTO Patent Public Search; it does not measure application filings, current R&D, or legal strength. Primary class: C07K (Peptides).

RSS updates for this company
Explore the portfolio See the ranking

The verdict

According to USPTO PatentsView, Wuhan ranks #30,623 of 49,997 tracked US assignees by granted-patent volume, with 9 patents across 4 technology areas.

#30,623
of 49,997 US assignees by volume
10th percentile
by Innovation Score (22.1/100)
6.2
avg claims per patent
-40%
grant velocity, last 5 yrs

USPTO PatentsView assignee plate

Corpus R30623 · Foreign Corporation #30,623 · 9 grants

GRANTS-MICRO · MID-PACK · PHOTO-FINISH · CPC-NARROW · INNOV-THIN · CLAIMS-SPARSE · TYPE-FRNCORP · VEL-DOWN · BOOK-FULL

  • GRANTS-MICRO 9 grants
  • MID-PACK #30,623/49,997
  • PHOTO-FINISH Wisenstech
  • CPC-NARROW C07K · 4 areas
  • INNOV-THIN 22.1/100
  • CLAIMS-SPARSE 6.2 claims/avg
  • TYPE-FRNCORP Foreign Corp
  • VEL-DOWN -40% vel
  • BOOK-FULL 10/10 fields

Nearest grant-volume peer: Wisenstech Ltd. (±0 grants)

Instrument codes from this assignee’s USPTO PatentsView grant sheet: volume band, corpus rank, photo-finish peer, lead CPC, Innovation Score, claim depth, assignee type, velocity, and book completeness. Not a USPTO rating of patent strength.

How Wuhan’s 22.1 Innovation Score adds up

The same four weighted components behind every Innovation Score on PlainPatent: portfolio volume, grant velocity, technology breadth, and claim depth.

Innovation-score neighbourhood around Wuhan

Lowest and highest poles plus nearest Innovation Score peers, not a full corpus board reprint.

score

What this shows Wuhan's Innovation Score is 22.1/100 (10th percentile of the PatentsView-derived corpus). The chart places that score against the nearest Innovation Score peers plus corpus poles, not a reprint of the volume ranking.

Source USPTO PatentsView, PlainPatent Innovation Score As of 2015–2025

Does more volume mean deeper claims for Wuhan?

Each dot is one of Wuhan’s 8 nearest volume peers (same corpus rank neighbourhood as the chart above), placed by total granted patents (horizontal) against average claims per patent (vertical). Wuhan’s own 6.2 claims/patent is at or below the 10.4 median for these volume peers. Volume here does not track with deeper claims; several lower-volume peers claim more thoroughly per patent.

Wuhan vs its 8 nearest volume peers: granted patents vs average claims per patent. Source: USPTO PatentsView. 2×2 strategic matrix plotting 9 entities by Granted patents (volume) (X) and Avg claims / patent (Y), with a crosshair dividing the plot into four quadrants. Volume + depthSelective & thoroughVolume over depthLean filer 8.98.999.1 05101520 Granted patents (volume) Avg claims / patent Wisenstech Ltd. - 9, 10.44WisenstechWonderhealth, LLC - 9, 16.67WonderhealthWorld Energy Systems Incorporated - 9, 17.89World Energy Syst…Wuhan Lewei E-Commerce Co., Ltd. - 9, 1Wuhan Lewei E-com…Wuxi Huaying Microelectronics Technology Co., Ltd - 9, 11.78Wuxi Huaying Micr…Wuyi Hongling Indusry and Trade Co., Ltd. - 9, 1Wuyi Hongling Ind…Wynalda Litho, Inc. - 9, 17.89Wynalda LithoWÖHNER Besitz GMBH - 9, 10.11WÖHNER BesitzWuhan YZY Biopharma Co., Ltd. - 9, 6.22Wuhan YZY Biophar…
Wuhan vs its 8 nearest volume peers: granted patents vs average claims per patent. Source: USPTO PatentsView.

Where Wuhan's grants concentrate

Wuhan YZY Biopharma Co., Ltd. is a focused PatentsView assignee: 4 CPC subclasses with 100% of grants classified under C07K (Peptides). Peak complete grant year is 2017 (3 grants) versus a trough of 1 in 2015. By volume, Wuhan sits between Wisenstech Ltd. and WÖHNER Besitz GMBH.

Wuhan's three-year grant acceleration

Wuhan YZY Biopharma Co., Ltd. shows 1 grants in 2022–2024 against only 2 in 2019–2021. That prior window is too thin for a growth multiple (rename and spin-out assignees look artificially high when the baseline is near zero), so PlainPatent withholds a ranked acceleration claim here.

Who files at Wuhan's volume?

Granted US patents 2015–2025 versus its nearest-ranked assignees by volume, this company marked ◀

patents

What this shows Wuhan holds 9 patents at rank #30,592, shown against the 8 assignees closest to it in grant volume rather than the industry's largest filers.

Source USPTO PatentsView, granted utility patents As of 2015–2025

Companies ranked near Wuhan

By rank, the assignees closest to #30,592 in granted patent volume.

Leaders in C07K (Peptides)

Other assignees with the most granted patents in Wuhan's primary technology class.

Wuhan's Innovation Score vs. every tracked assignee

Composite of portfolio volume, grant velocity, technology breadth, and claim depth (0–100)

22 10th percentile higher than 10% of 49,997 US assignees

This assignee 0 100 every tracked assignee, bucketed by value

Each bar is a band; taller bars hold more US assignees. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count, share, and where it sits relative to this entry.

Source USPTO PatentsView, PlainPatent Innovation Score · 2015–2025

0.511.522.533.5 201520172018202020232025 1
USPTO utility patent grants by year · 2015–2025

Grants by year

Teal-shaded recent years (2020–present) versus the 2015–2019 baseline. Full figures in the table below.

View data table
Wuhan YZY Biopharma Co., Ltd. patent grants by year, 2015–2025
Year Patents Granted Share of Period
2015 1 11.1%
2017 3 33.3%
2018 1 11.1%
2020 2 22.2%
2023 1 11.1%
2025partial year 1 11.1%

Which technologies does Wuhan YZY Biopharma Co., Ltd. patent most?

Top 4 of 4 technology areas

More on this record

Data Source

USPTO PatentsView, US granted patents 2015–2025

View all rankings → How is Innovation Score calculated?

What to do with this data

Wuhan YZY Biopharma Co., Ltd.'s patent record in context - here's where to go next.

  • Wuhan YZY Biopharma Co., Ltd.'s lead technology class is C07K (Peptides), 100% of its portfolio - see every assignee active in that class. Explore C07K
  • Ranked #30,623 of 49,997 tracked assignees by patent volume - see the full leaderboard. See the ranking
  • Compare Wuhan YZY Biopharma Co., Ltd. against Wisenstech Ltd., an assignee filing at a similar volume. Compare portfolios
  • Innovation Score of 22.1/100 blends volume, velocity, technology breadth, and claim depth. How it's calculated

Figures reflect USPTO PatentsView grant data through May 2026; pending applications not yet granted are not counted.

Data sourced from USPTO PatentsView - official U.S. government patent data. See our methodology for computation details. Retrieved and formatted by PlainPatent

Disclaimer: This information is provided for informational purposes only and does not constitute professional advice. Data is sourced from the USPTO PatentsView database. Consult a qualified professional before making decisions based on this data.

Read our methodology - how this data is sourced, computed, and verified.

Data sources used on this page
  • USPTO PatentsView - the disambiguated bulk patent-grant, assignee, and CPC data this page's figures are derived from. patentsview.org
  • Cooperative Patent Classification (CPC) - the joint USPTO/EPO classification scheme used to group patents by technology area. cooperativepatentclassification.org
  • USPTO Patent Public Search - the official interface to verify the status of any individual patent. ppubs.uspto.gov

Every figure on PlainPatent is rendered directly from USPTO source data, no number is typed in by an editor. This page draws directly on USPTO source data, no figure is typed in by an editor. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error. Data current as of May 2026.